INTRODUCTION {#s1}
============

Programmed cell death ligand 1 (PD-L1), also known as B7 homolog 1 (B7H1), plays a critical role in T cells co-inhibition and exhaustion via the binding with programmed death 1 (PD-1) receptor expressed on activated T cells\[[@R1], [@R2]\]. Recently, it\'s reported that PD-L1 expressed on tumor cells can promote anergy or apoptosis of tumor antigen-specific T-cells, resulting in enhanced tumor cell growth and tumor immune evasion \[[@R2], [@R3]\].

PD-L1 expression has been observed in various solid tumors, including carcinomas of the esophagus, gastrointestinal tract, pancreas, breast, lung, and kidney \[[@R4]--[@R8]\]. Inhibition of the PD-1/PD-L1 axis may become a promising approach to restore host immunity against these tumors \[[@R9], [@R10]\].

Recent clinical trials show that blockage of PD-1/PD-L1 pathway with anti-PD-1 or anti-PD-L1 antibodies can produce durable remission in several different malignancies including, but not limited to, melanoma, lung, renal and bladder cancer\[[@R11]--[@R14]\]. Although the response is remarkable, the response rate is quite low, which means only a small subset of patients benefit from PD-1/PD-L1-directed immunotherapy \[[@R15], [@R16]\]. Further research has demonstrated that clinical response was closely associated with PD-L1 expression\[[@R17]\]. However, screening the target population is difficult due to a lack of uniform standard in PD-L1 detection \[[@R18]\]. Therefore, determining the subset of patients with positively expressed PD-L1 in tumor cells is of great clinical significance, particularly in light of the autoimmune toxicity of immunotherapy.

A number of recent studies have reported on the clinicopathologic features of PD-L1 positive cancer. However the results of these studies were not consistent and sample sizes were relatively modest. Since PD-L1/PD-1 is a common pathway that functions in a wide spectrum of cancers, we performed a meta-analysis by incorporating all the available evidence to evaluate the association between clincopathological features and PD-L1 expression, aiming to identify those with high PD-L1 expression that may benefit from anti-PD-L1 therapy.

RESULTS {#s2}
=======

Search results {#s2_1}
--------------

Our initial search yielded 1158 potential literature citations. Of these, 863 were excluded after scanning titles and abstracts, leaving 295 citations for full-text assessment. Of the 295, 61 studies met the inclusion criteria and were used for this meta-analysis. The remaining studies were excluded largely because of the following reasons: (I) reported data regarding clinicopathological features was not stratified by PD-L1 status, (II) the data was reported in an unsuitable format and therefore unable to be compared to the others studies, or (III) they included data that overlapped with other studies. (Figure [1](#F1){ref-type="fig"})

![Flow chart of study selection](oncotarget-07-15033-g001){#F1}

Characteristics of the studies {#s2_2}
------------------------------

Baseline characteristics of the studies included are shown in Table [1](#T1){ref-type="table"}. The 61 included studies covered 17 types of epithelial-originated malignancies, including adrenocortical carcinoma (AC) breast cancer (BC), cervical carcinoma (CC), clear cell renal cell carcinoma (CRCC), non-clear cell renal cell carcinoma (NCRCC), colorectal cancer (CRC), esophageal cancer (EC), gastric carcinoma (GC), hepatocellular carcinoma (HCC), head and neck cancer (HNC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), pancreatic cancer (PC), plural mesothelium, skin cancer (SK), thymic carcinoma (TC) and urothelial cell carcinoma (UCC). The total number of patients of epithelial-originated cancer was 9212, including 4068 cases of Asian origin. The overall expression rate of PD-L1 was 44.5% (95% CI, 37.5% to 51.6 %). Mouse-originated monoclonal antibody accounted for the vast majority in terms of primary anti-PD-L1/PD-1 antibody. In the subgroup analysis of PD-L1 expression rate (more details are in Table [2](#T2){ref-type="table"}), we found a numerically higher PD-L1 expression rate when using polyclonal antibodies 57.2% (95% CI 49.8% to 64.6%) than monoclonal antibodies 39.6% (95% CI 32.8% to 46.3%). In addition, the PD-L1 expression rate reported by studies from Asian areas was numerically higher than those from non-Asian areas, namely Caucasians 52.3% (95% CI 46.9% to 57.6%) and 32.7% (95% CI 24.3% to 41.1%) respectively. Not all studies reported on all variables examined in the meta-analysis; therefore, only studies that reported the variable of interest were analyzed for PD-L1 association with that variable. Funnel plots with the Begg\'s tests of different clinicopathological parameters were shown as [Supplementary Figure S1](#SD1){ref-type="supplementary-material"}.

###### Characteristics of included studies for meta-analysis

  Lead author (y)           Tumor type                   Patients\' origin   IHC evaluation[^a^](#tfn_001){ref-type="table-fn"}   Cut-off value for PD-L1 positive            Antibody                                      PD-L1 positive/total   PD-L1 positive (%)                              
  ------------------------- ---------------------------- ------------------- ---------------------------------------------------- ------------------------------------------- --------------------------------------------- ---------------------- -------------------- --------------- ---------- -------
  Fay(2015)                 AC                           Non-Asia            Percentage                                           ≥5%                                         NA                                            NA                     MAB                  NA              3/28       10.71
  GhebehH(2006)             BC                           Asia                Percentage                                           ≥5%                                         eBioscience, USA                              Mouse                  MAB                  clone MIH1      13/44      29.55
  Ghebeh H(2008)            BC                           Asia                Percentage                                           ≥5%                                         eBioscience, USA                              Mouse                  MAB                  clone MIH1      19/62      30.65
  Mittendorf EA(2014)       BC                           Non-Asia            Percentage                                           ≥5%                                         Lieping Chen, Yale University                 Mouse                  MAB                  clone 5H1       20/105     19.04
  Muenst S(2014)            BC                           Non-Asia            H-score                                              ≥100                                        Abcam, UK                                     Rabbit                 PAB                  NA              152/650    23.38
  Karim R(2009)             CC                           Non-Asia            Percentage                                           \>0                                         Lieping Chen, Yale University                 Mouse                  MAB                  clone 5H1       22/115     19.13
  Droeser RA(2013)          CRC                          Non-Asia            H-score                                              ≥200                                        MBL, USA                                      Mouse                  MAB                  clone 27A2      669/1420   47.11
  Hua D(2012)               CRC                          Asia                H-score                                              ≥200                                        NA                                            NA                     NA                   NA              15/33      45.45
  Liang M(2014)             CRC                          Asia                H-score                                              ≥20                                         Santa Cruz Biotechnology, USA                 Rabbit                 PAB                  NA              102/185    55.14
  Shi SJ(2013)              CRC                          Asia                H-score                                              ≥200                                        Abcam, UK                                     Rabbit                 PAB                  ab58810         64/143     44.76
  Zhang MY(2012)            CRC                          Asia                Percentage                                           ≥10%                                        NA                                            NA                     NA                   NA              26/57      45.61
  Zhao LW(2014)             CRC                          Asia                H-score                                              ≥20                                         eBioscience, USA                              Mouse                  MAB                  clone MIH1      27/56      48.21
  Krambeck AE(2007)         CRCC                         Non-Asia            Percentage                                           ≥5%                                         Lieping Chen, Yale University                 Mouse                  MAB                  clone 5H1       70/298     23.49
  Thompson RH(2005)         CRCC                         Non-Asia            Percentage                                           ≥5%                                         Lieping Chen, Yale University                 Mouse                  MAB                  clone 5H1       103/196    52.55
  Thompson RH(2006)         CRCC                         Non-Asia            Percentage                                           ≥5%                                         Lieping Chen, Yale University                 Mouse                  MAB                  clone 5H1       73/306     23.86
  Thompson RH(2007)         CRCC                         Non-Asia            Percentage                                           ≥10%                                        Lieping Chen, Yale University                 Mouse                  MAB                  clone 5H1       142/267    53.18
  Loos M(2011)              EC                           Non-Asia            H-score                                              ≥66                                         Abcam, UK                                     Rabbit                 PAB                  NA              37/101     36.63
  Ohigashi Y(2005)          EC                           Asia                Percentage                                           ≥10%                                        eBioscience, USA                              Mouse                  MAB                  clone MIH1      18/41      43.9
  Shohei Eto(2015)          GC                           Asia                H-score                                              ≥51                                         Abcam, Cambridge, UK                          Rabbit                 MAB                  ab174838        28/105     26.7
  Geng Y(2014)              GC                           Asia                H-score                                              ≥22                                         Novus, USA                                    Mouse                  MAB                  clone 2H11      65/100     65
  Hou J(2014)               GC                           Asia                Percentage                                           ≥10%                                        Abcam, UK                                     Rabbit                 PAB                  NA              70/111     63.06
  Wu C(2006)                GC                           Asia                NA                                                   NA                                          Novus, USA                                    Mouse                  MAB                  clone 2H11      43/102     42.16
  Gao Q(2009)               HCC                          Asia                H-score                                              ≥75th percentile                            eBioscience, USA                              Mouse                  MAB                  clone MIH1      60/240     25
  Wang BJ(2011)             HCC                          Asia                H-score                                              ≥10                                         eBioscience, USA                              Mouse                  MAB                  clone MIH1      24/26      92.31
  Cho YA(2011)              HNC                          Asia                H-score                                              ≥Median                                     Abcam, UK                                     Rabbit                 PAB                  ab82059         26/45      57.78
  Oliveira-Costa JP(2015)   HNC                          Non-Asia            NA                                                   NA                                          NA                                            NA                     NA                   NA              47/96      48.96
  Ukpo OC(2013)             HNC                          Asia                Percentage                                           ≥5%                                         NA                                            NA                     MAB                  clone A3        84/181     46.41
  Zhang F(2008)             HNC                          Asia                Percentage                                           ≥10%                                        Boster, China                                 Rabbit                 PAB                  BA2495          40/59      67.8
  Choueiri(2014)            NCRCC                        Non-Asia            Percentage                                           ≥5%                                         Dana-Farber Cancer Institute, Boston, MA      mouse                  MAB                  405.9A11        11/101     10.89
  Azuma K(2014)             NSCLC                        Asia                H-score                                              \>30                                        Lifespan Biosciences, WA                      Rabbit                 PAB                  NA              82/164     50
  Boland JM(2013)           NSCLC                        Non-Asia            Percentage                                           ≥5%                                         Laboratory developed                          NA                     NA                   clone 5H1       42/214     19.63
  Chen YB(2012)             NSCLC                        Asia                H-score                                              ≥3                                          Abcam, HK                                     Rabbit                 PAB                  clone 236A/E7   69/120     57.5
  Chen YY(2013)             NSCLC                        Asia                H-score                                              \>9                                         Abcam, HK                                     Rabbit                 PAB                  NA              136/208    65.38
  Cooper, W. A(2015)        NSCLC                        Non-Asia            percentage                                           ≥50%                                        Merck                                         Mouse                  MAB                  clone22C3       628/678    92.6
  D\'Incecco(2015)          NSCLC                        Non-Asia            H-score                                              ≥10                                         Abcam, UK                                     Rabbit                 PAB                  ab58810         68/123     55.3
  Jiang(2015)               NSCLC                        Asia                Percentage                                           ≥5%                                         Abcam, UK                                     Rabbit                 PAB                  NA              50/79      63.29
  Kim(2015)                 NSCLC                        Asia                H-score                                              ≥30                                         Cell Signaling Technology, Danvers, MA, USA   NA                     MAB                  E1L3N           89/331     26.89
  Mu CY(2011)               NSCLC                        Asia                H-score                                              ≥Median value                               NA                                            NA                     MAB                  NA              58/109     53.21
  Velcheti V(2014)          NSCLC (Yale U. cohort)       Non-Asia            DIA                                                  NA                                          Lieping Chen, Yale University                 Mouse                  MAB                  clone 5H1       56/155     36.13
  Velcheti V(2014)a         NSCLC(Greek cohort)          Non-Asia            DIA                                                  NA                                          Lieping Chen, Yale University                 Mouse                  MAB                  clone 5H1       75/303     24.75
  Yang CY(2014)             NSCLC                        Asia                Percentage                                           ≥5%                                         Proteintech Group Inc., USA                   Rabbit                 PAB                  17952-1-AP      65/163     39.88
  Yih-Leong Chang(2015)     NSCLC                        Asia                NA                                                   NA                                          Proteintech Group Inc                         Rabbit                 PAB                  NA              50/66      75.76
  Zhang Y(2014)             NSCLC                        Asia                H-score                                              ≥60                                         Sigma-Aldrich, USA                            Rabbit                 PAB                  SAB2900365      70/143     48.95
  Ishii(2015)               SCLC                         Asia                Percentage                                           ≥5%                                         Abcam, UK                                     Rabbit                 PAB                  NA              73/102     71.56
  Chen XL(2009)             PC                           Asia                Percentage                                           ≥10%                                        Novus, USA                                    Mouse                  MAB                  clone 2H11      18/40      45
  Geng L(2008)              PC                           Asia                Percentage                                           ≥10%                                        R&D systems                                   Mouse                  MAB                  Clone130002     23/40      57.5
  Nomi T(2007)              PC                           Asia                Percentage                                           ≥10%                                        eBioscience, USA                              Mouse                  MAB                  clone MIH1      20/51      39.22
  Wang L(2010)              PC                           Asia                Percentage                                           ≥5%                                         eBioscience, USA                              Mouse                  MAB                  clone MIH1      40/81      49.38
  SusanaCedrés(2015)        Plural mesothelium           Non-Asia            Percentage                                           ≥1%                                         Cell Signaling Technology, Danvers, MA, USA   Rabbit                 MAB                  cloneE1L3N      16/77      20.78
  Gadiot J(2011)            SC (Melanoma)                Non-Asia            Percentage                                           ≥1%                                         R&D Systems, USA                              Mouse                  MAB                  156-B7-100      16/63      25.4
  Hino R(2010)              SC (Melanoma)                Asia                DIA                                                  RD[^b^](#tfn_002){ref-type="table-fn"}≥90   MBL, Japan                                    Mouse                  MAB                  clone 27A2      34/59      57.63
  Oba J(2014)               SC (Melanoma)                Asia                Percentage                                           ≥5%                                         eBioscience, USA                              Mouse                  MAB                  clone MIH1      36/77      46.75
  Taube JM(2012)            SC (Melanoma)                Non-Asia            Percentage                                           ≥5%                                         Lieping Chen, Yale University                 Mouse                  MAB                  clone 5H1       57/150     38
  Lipson EJ(2013)           SC (Merkel cell carcinoma)   Non-Asia            Percentage                                           ≥5%                                         Lieping Chen, Yale University                 Mouse                  MAB                  clone 5H1       24/49      48.98
  Katsuya (2015)            TC                           Asia                H-score                                              3                                           Cell Signaling Technology, Danvers, MA, USA   Rabbit                 MAB                  NA              48/139     34.53
  Boorjian SA(2008)         UCC                          Non-Asia            Percentage                                           ≥5%                                         Lieping Chen, Yale University                 Mouse                  MAB                  clone 5H1       39/314     12.42
  Faraj (2015)              UCC                          Non-Asia            Percentage                                           ≥5%                                         NA                                            Mouse                  MAB                  clone 5H1       10/56      17.86
  Inman BA(2007)            UCC                          Non-Asia            Percentage                                           ≥1%                                         Lieping Chen, Yale University                 Mouse                  MAB                  clone 5H1       77/280     27.5
  Nakanishi J(2006)         UCC                          Asia                Percentage                                           ≥2.1%                                       eBioscience, USA                              Mouse                  MAB                  clone MIH1      46/65      70.77
  Wang Y(2009)              UCC                          Asia                Percentage                                           \>10%                                       Santa Cruz Biotechnology, USA                 Rabbit                 PAB                  NA              36/50      72
  Wang YH(2014)             UCC                          Asia                Percentage                                           ≥10%                                        Boster, China                                 Rabbit                 PAB                  BA2495          43/60      71.67

H-score = SI (staining intensity) × PP (percentage of positive cells). SI was determined as: 0, negative; 1, weak; 2, moderate; and 3, strong. PP was defined as: 0, negative; 1-100, 1-100% positive cells

Digitized specimens were exported to JPG files by using NDP View software (Hamamatsu Photonics). Three different areas from the tumor cell cytoplasm were selected and expressed as Red channel histograms. Histograms revealed 255 different shades from pitch black (0) to pure white (255), and a number represented the level of brightness of each color. RD (red density) values represent the mean of each color

Abbreviations: AC = adrenocortical carcinoma; BC = breast cancer; CC = cervical carcinoma; CRCC = clear cell renal cell carcinoma; NCRCC = non-CRCC; CRC = colorectal cancer; EC = esophageal cancer; GC = gastric carcinoma; HCC = hepatocellular carcinoma; HNC =head and neck cancer; SCLC = small cell lung cancer; NSCLC = non-SCLC; PC = pancreatic cancer; SC=skin cancer; TC = thymic carcinoma; UCC = urothelial cell carcinoma; DIA = digital image analysis; IHC = immunohistochemistry; MAB = monoclonal antibody; NA = not available; PAB= polyclonal antibody; PD-L1 = Programmed cell death ligand 1.

###### Summary of PD-L1 expression rate in subgroup analysis

  Subgroup                              *No*. of studies   PD-L1 expresson rate (95% CI) / %   Subgroup                        *No*. of studies   PD-L1 expression rate (95% CI) / %
  ------------------------------------- ------------------ ----------------------------------- ------------------------------- ------------------ ------------------------------------
  **Tumor type**                                                                               **Patients\' origin**                              
  adrenocortical carcinoma              1                  10.7 (−0. 7-22.1)                   Asian                           37                 52.3 (46.9-57.6)
  Breast cancer                         4                  23.7 (19.9-27.4)                    Non-Asian                       24                 32.7 (24.3- 41.1)
  Cervical carcinoma                    1                  19.1 (11.9-26.3)                    **Antibody-Type**                                  
  Clear cell renal cell carcinoma       4                  38.1 (22.0-54.2)                    Monoclonal antibody             39                 39.6 (32.8-46.3)
  Non-clear cell renal cell carcinoma   1                  10.9 (4.8-17.0)                     Polyclonal antibody             18                 57.2 (49.8-64.6)
  Colorectal cancer                     6                  47.7 (45.4-49.9)                    **IHC evaluation**                                 
  Esophageal cancer                     2                  38.6 (30.7-46.6)                    Percentage                      35                 42.8 (31.5-54.2)
  Gastric carcinoma                     4                  49.2 (30.8-67.6)                    H-score                         20                 47.7 (40.5-54.9)
  Hepatocellular carcinoma              2                  58.5 (−7.5-124.5)                   DIA                             3                  24.9 (20.4-29.3)
  Small cell lung cancer                1                  71.6 (62.8-80.3)                    NA                              3                  55.6 (35.7-75.4)
  Non-small cell lung cancer            13                 51.7 (33.1-70.3)                    **IHC evaluation-Percentage**                      
  Pancreatic cancer                     4                  47.6 (40.5-54.6)                    Cut-off = 5%                    19                 34.3 (26.5-42.1)
  plural mesothelium                    1                  20.8 (11.7-29.8)                    Cut-off = 10%                   10                 56.5 (49.5-63.6)
  Head and neck cancer                  4                  54.4 (44.8-60.0)                    Others                          6                  42.9 (7.3-78.5)
  Skin cancer                           5                  42.8 (32.5-53.1)                    **IHC evaluation-H-score**                         
  Thymic carcinoma                      1                  34.5 (26.6-42.4)                    Cut-off ≤ 50                    10                 54.8 (43.1-66.5)
  Urothelial carcinoma                  6                  44.9 (24.4-65.4)                    Cut-off \> 50                   8                  37.1 (27.8-46.5)

Abbreviations: CI = confidence interval; IHC = immunohistochemistry; DIA = digital image analysis; NA = not available; PD-L1 = programmed cell death 1ligand 1.

Correlation of PD-L1 expression and clinicopathological features {#s2_3}
----------------------------------------------------------------

### Age {#s2_3_1}

Twenty-nine studies, including 3845 patients, were analyzed for the association between PD-L1 expression and age. Of 1909 elder patients, 821 (43.0%) were PD-L1 expression positive, and 821 (42.4%) of 1936 younger patients were PD-L1 expression positive. No significant association was found between PD-L1 expression and age (OR 1.04, 95% CI 0.90 to 1.20; P = 0.58) (Figure [2A](#F2){ref-type="fig"}).

![Forest plot for the association between PD-L1 expression and clinicopathological features\
**A.** age, **B.** gender. Events refer to cases with PD-L1 positive expression. ORs with corresponding 95 % CIs of individual studies and overall are shown in the forest plot. Abbreviations: OR = odds ratio; CI = confidence interval; LNM= lymph node metastasis; PD-L1= Programmed cell death ligand 1. **C.** tumor size, **D.** lymph node metastasis. Events refer to cases with PD-L1 positive expression. ORs with corresponding 95 % CIs of individual studies and overall are shown in the forest plot. Abbreviations: OR = odds ratio; CI = confidence interval; LNM= lymph node metastasis; PD-L1= Programmed cell death ligand 1. **E.** tumor cell differentiation. Events refer to cases with PD-L1 positive expression. ORs with corresponding 95 % CIs of individual studies and overall are shown in the forest plot. Abbreviations: OR = odds ratio; CI = confidence interval; LNM= lymph node metastasis; PD-L1= Programmed cell death ligand 1.](oncotarget-07-15033-g002){#F2}

### Gender {#s2_3_2}

Thirty-eight studies, including 6675 patients, were analyzed for the association between PD-L1 expression and gender. Of 4309 male patients, 2298 (53.3%) were PD-L1 expression positive, and 1404 (59.3%) of 2366 female patients were PD-L1 expression positive. No significant association was found between PD-L1 expression and gender (OR 1.13, 95% CI 0.99 to 1.29; P = 0.06) (Figure [2B](#F2){ref-type="fig"}).

### Tumor size {#s2_3_3}

The association between PD-L1 expression and size of tumor was analyzed in Thirty-eight studies, including a total of 6273 patients. Of 3417 tumors of large size, 1953 (57.6%) were PD-L1 expression positive, and 1070 (37.5%) of 2856 small size tumors were PD-L1 expression positive. There was a significant association betweenPD-L1 expression and tumors of large size (OR 1.89, 95% CI 1.66 to 2.16; P \< 0.01) (Figure [2C](#F2){ref-type="fig"}).

### Lymph node metastasis {#s2_3_4}

Thirty-four studies, including 6300 patients, were analyzed for the association between PD-L1 expression and lymph node metastasis. Of 2530 lymph node-positive patients, 1354 (53.5%) tested positive for PD-L1 expression, and 1443 (38.3%) of 3770 lymph node-negative patients tested positive for PD-L1 expression. A significant association was found between PD-L1 expression and the presence of lymph node metastases (OR 1.38, 95% CI 1.20 to 1.58; P \< 0.01) (Figure [2D](#F2){ref-type="fig"}).

### Differentiation {#s2_3_5}

Twenty-three studies, including 4735 patients, were analyzed for the association of PD-L1 expression and differentiation of tumor cells. Of 1791 patients with poor tumor differentiation (grade III), 668 (37.3%) were PD-L1 expression positive, and 880 (29.9%) of 2944 patients with well differentiation (grade I/II) were PD-L1 expression positive. A significant association exists between PD-L1 expression and tumor cell differentiation (OR 1.71, 95% CI 1.48 to 1.98; P \< 0.01) (Figure [2E](#F2){ref-type="fig"}).

### Subgroup analysis {#s2_3_6}

Further subgroup analysis was performed by stratifying the studies according to the patients\' origins (Asian & Non-Asian), primary anti-PD-L1 antibodies (monoclonal antibody & polyclonal antibody), IHC evaluation for PD-L1 (percentage & H-score), cut-off values for percentage (5% & 10%) and H-score (≤ 50 & \> 50). The conclusions drawn from the subgroup analyses are similar to that of the overall analysis (more details are listed in Table [3](#T3){ref-type="table"}).

###### Summary of subgroup analyses results in studies reported PD-L1 status stratified by clinicopathlogical features

  Subgroup                            No. of studies; OR \[95% CI\]                                                                                 
  ----------------------------------- ------------------------------- ------------------------- ------------------------- ------------------------- -------------------------
  **Patients\' origin**                                                                                                                             
  Asian                               24; 1.03 \[0.87, 1.22\]         26; 1.19 \[1.01, 1.41\]   27; 1.75 \[1.48, 2.08\]   14; 1.58 \[1.24, 2.02\]   20; 1.53 \[1.26, 1.87\]
  Non-Asian                           5; 1.07 \[0.82, 1.41\]          12; 1.05 \[0.85, 1.29\]   11; 2.13 \[1.73, 2.62\]   9; 1.78 \[1.49, 2.14\]    14; 1.24 \[1.02, 1.50\]
  **Primary anti-PD-L1 antibodies**                                                                                                                 
  Monoclonal antibody                 15; 1.04 \[0.86, 1.26\]         21; 1.11 \[0.94, 1.32\]   24; 1.85 \[1.57, 2.19\]   13; 1.62 \[1.34, 1.96\]   23; 1.16 \[0.96, 1.41\]
  Polyclonal antibody                 13; 1.08 \[0.86, 1.34\]         16; 1.18 \[0.96, 1.45\]   13; 2.00 \[1.61, 2.48\]   9; 1.73 \[1.37, 2.18\]    11; 1.68 \[1.37, 2.06\]
  **IHC evaluation**                                                                                                                                
  Percentage                          12; 0.98 \[0.76, 1.26\]         18; 1.16 \[0.95, 1.41\]   22; 2.16 \[1.79, 2.61\]   12; 2.61 \[2.07, 3.31\]   16; 1.61 \[1.23, 2.10\]
  H-score                             11; 1.09 \[0.88, 1.34\]         14; 1.14 \[0.93, 1.39\]   14; 1.58 \[1.30, 1.91\]   10; 1.32 \[1.09, 1.61\]   12; 1.37 \[1.13, 1.65\]
  **IHC evaluation-Percentage**                                                                                                                     
  Cut-off = 5%                        7; 0.97 \[0.70, 1.34\]          10; 1.17 \[0.92, 1.48\]   13; 2.15 \[1.71, 2.71\]   5; 3.50 \[2.45, 4.98\]    11; 1.82 \[1.31, 2.53\]
  Cut-off = 10%                       5; 0.99 \[0.67, 1.46\]          6; 1.12 \[0.71, 1.77\]    10; 2.31 \[1.66, 3.20\]   6; 1.84 \[1.28, 2.64\]    4; 1.66 \[1.00, 2.78\]
  **IHC evaluation-H-score**                                                                                                                        
  Cut-off ≤ 50                        7; 1.20 \[0.92, 1.57\]          8; 1.17 \[0.90, 1.52\]    6; 1.30 \[0.96, 1.76\]    3; 1.82 \[1.16, 2.87\]    4; 1.20 \[0.86, 1.69\]
  Cut-off \> 50                       2; 0.94 \[0.59, 1.49\]          5; 1.12 \[0.81, 1.54\]    7; 1.81 \[1.41, 2.33\]    5; 1.14 \[0.91, 1.43\]    6; 1.50 \[1.17, 1.91\]

Abbreviations: CI = confidence interval; OR = Odds ratio; IHC = immunohistochemistry; LNM = lymph node metastasis; PD-L1 = programmed cell death 1ligand 1.

DISCUSSION {#s3}
==========

For patients with epithelial-originated malignancies, the association between clinicopathological features and PD-L1 expression remains unclear. A meta-analysis incorporating all available data from correlative studies is a reasonable method to clarify this issue. Through the completion of this meta-analysis we found that epithelial-originated cancer with regional lymph node metastasis, large size tumors, or well differentiated tumors were associated with higher PD-L1 expression rate. We also found that polyclonal antibodies detected a numerically higher PD-L1 expression rate than monoclonal antibodies. Additionally, PD-L1 expression rates reported in studies from Asian areas were numerically higher than those from non-Asian areas namely Caucasians.

We might infer the following as the basis for the positive correlation of PD-L1 expression with large tumor size and lymph node metastasis: under normal conditions, the genetic and epigenetic alterations can distinguish the cancer cells from the normal counterparts, allowing tumors to be recognized and repelled as foreign by the immune system \[[@R19]\]. When PD-L1 is highly expressed on tumor cells, its engagement with PD-1, an important co-inhibitor on the T cell, can block the T cell cytotoxicity and lead to T-cell exhaustion\[[@R9]\]. Binding of PD-L1 to PD-1 on naive tumor-infiltrating lymphocytes (TILs) can arrest the process of antigen presenting at the effector phase and suppress T-cell activation, migration, proliferation and secretion of cytotoxic mediators. Interaction of PD-L1 with PD-1 can also increase apoptosis of tumor specific CD8+ cells \[[@R20]\]. What\'s more, PD-L1 acts not only as a ligand of PD-1, but can also serve as a receptor transmitting reverse signals that protect cancers cells from apoptosis mediated by FAS-FASL pathway \[[@R21]\]. These actions of PD-L1 expressed on the tumor can thereby dampen the antitumor immunity and contribute the over growth and metastasis of the tumor cells.

The positive correlation between PD-L1 expression and poor differentiation of tumors found in this meta-analysis is consistent with the majority of other studies, though the underlying mechanism remains unclear. Poor differentiation may be associated with over proliferating effect of the PD-L1 positive tumor cells. Quite a lot published evidences have shown that PD-L1 expression promote tumor cell proliferation indirectly through both exogenous and intrinsic pathway. On one hand, exogenous stimulus delivered by the pro-inflammatory cytokines in the inflammatory microenvironment can trigger the receptor mediated signaling molecules within the tumor cells (including NF-κB, MAPK, PI3K, mTOR, and JAK/STAT) that promote cell proliferation, and induce PD-L1 expression as well \[[@R22]\]. On the other hand, some intrinsic oncogenic pathway (like anaplastic lymphoma kinase in lung cancer \[[@R23]\], loss of tumor suppressor phosphate and tension homolog in pancreatic cancer \[[@R24]\] etc.) have been reported to drive PD-L1 expression and, in the meanwhile, are involved in key cellular functions such as proliferation, growth, and survival \[[@R25]--[@R27]\]. Over proliferation of the tumor cells is usually accompanied with cellular de-differentiation, which explains the positive correlation between poor differentiation and PD-L1 over expression of the tumor cells.

With regard to the immune evasion of solid tumor mediated by PD-1/PD-L1 immune-checkpoint pathway, a series of specific inhibitors are currently under investigation and in clinical development such as nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, pembrolizumab (formerly known as MK-3475 or lambrolizumab), a high affinity humanized IgG4 monoclonal antibody targeting PD-1, and MPDL3280A, an engineered IgG anti-PD-L1 antibody \[[@R11], [@R12], [@R15], [@R28]\]. Among these, pembrolimumab and nivolumab \[[@R29], [@R30]\] have been approved by the US Food and Drug administration (FDA) in the treatment of advanced melanoma and non-small cell lung cancer for their remarkably durable clinical response. Along with that, two different immunohistochemical (IHC) assays that linked to the use of pembrolizumab and nivolumab will come into the market for PD-L1 expression detection\[[@R31]\]. Although the therapeutic effect of anti-PD-1/PD-L1 treatment is unprecedented, the response rate in the context of unselected population affected by advanced solid tumors was barely satisfactory, ranging from 10% to 45% \[[@R32]--[@R34]\]. In light of the expense and adverse effects of anti-PD-1/PD-L1 therapy, further exploration is warranted to identify the proportion of patients most likely to benefit from the immunotherapy and thus optimize their therapeutic index. More and more evidences indicated that PD-L1 expression level in tumor cells is positively correlated with the response rate \[[@R17], [@R35]\]. It\'s well known that epidermal growth factor receptor gene (*EGFR*) mutation status has a similar predictive role in the efficacy of EGFR-targeting therapy for patients with non-small cell lung cancer (NSCLC) \[[@R34]\]. But what differs PD-L1 from the EGFR protein is the lack of a clear-cut gene-mediated pathway that exclusively contributes to the over expression of PD-L1. That means we can\'t precisely identify PD-L1 status at the gene level as multiple (intrinsic and extrinsic) signaling pathways are involved in the induction of PD-L1 expression \[[@R37]\]. As for the quantitative or semi-quantitative detection of PD-L1 by immunohistochemistry (IHC), its reliance and reproducibility is still disputed due to the lack of uniform antibody and cut-off values, which consequently restricts its application in screening candidate patients for the immunotherapy. What\'s more, PD-L1 expression may change dynamically during the process of tumor progression. It\'s unreliable to decide PD-L1 status by IHC detection at a single time point. Considering the dilemma of PD-L1 detection in clinical practice, a more practical way of patients\' stratification is warranted. The elucidation of the relationship between PD-L1 expression and clinicopathological parameters in this meta-analysis provides a convenient way to identify patients that are most likely to have a high level of PD-L1 expression on the tumor cells and thus provides rationale for patients\' stratification in clinical practice. According to our pooled analysis, patients with larger tumor size, lymph node metastasis, or poorly differentiated tumors tend to have higher level of PD-L1 expression; these patients may benefit more from treatment targeting PD-1/PD-L1 pathway. What\'s more, as these clinicopathological parameters are also associated with advanced stage and poor prognosis, our results rationalize the application of anti-PD-1/PD-L1 immunotherapy in patients with advanced tumors that currently lack effective treatment options. It also indirectly proves that PD-L1 over expression is associated with poor prognosis of solid tumors as demonstrated by previous studies \[[@R38]\].

The higher expression rate of PD-L1 among patients of Asian origin, as shown in our results, may be associated with higher frequencies of virus-associated malignancies in Asian areas. PD-L1 over expression has been reported to be associated with viral infection and chronic inflammation \[[@R39]\]. Intratumoral expression of PD-L1 and/or PD-1 has been shown in polyomavirus-associated Merkel cell carcinoma \[[@R40]\], hepatitis B virus(HBV)-related hepatocellular carcinoma \[[@R41]\], human papillomavirus(HPV)-associated head and neck cancer \[[@R42]\], Epstein Barr Virus(EBV)-associated nasopharyngeal cancer \[[@R43]\] and so on. Our result implies that the immune associated PD-1/PD-L1 may play a significant role in the development and progression of virus associated cancer.

To the best of our knowledge, this is the first study to comprehensively demonstrate the relationship between PD-L1 status and clinicopathological parameters of solid tumors. However, several limitations existed: (I) Different tumors may have different biologic behaviors, but we failed to conduct this particular subgroup analysis as data for some tumor types was insufficient; (II) Cut-off values distinguishing high or low levels of PD-L1 expression determined by IHC evaluation and the primary antibodies varied in different types of tumors, which might cause heterogeneity of the overall results; (III) Different studies adopt different thresholds for the size of large tumors, as well as the age for elder patients, which can also lead to the heterogeneity of the pooled result. (IV) As a result of the lack of sufficient data, we were unable to evaluate the relationship between clinicopathological parameters and PD-1/PD-L1 status on the tumor infiltrating lymphocytes (TILs) which is also associated with immune evasion of tumor and responsiveness of immunotherapy.

Regardless of the above limitations, this comprehensive analysis demonstrates the relationship between PD-L1 expression and clinicopathological features of solid tumors. The results may lead to improvement in the outcome of anti-PD-1/PD-L1 therapy by guiding patients\' stratification in a convenient way. Further large-scale clinical studies should be performed to demonstrate the association between PD-L1 expression and clinicopathological characteristics in the subgroups of different tumor types. Further effort is also warranted to investigate the relationship between PD-1/PD-L1 status on TILs.

In summary, meta-analysis of the literature shows that PD-L1 over expression on the tumor cells correlates with poor prognostic features including large tumor size, lymph node metastasis and poor differentiation of solid tumors. The PD-L1 expression rate in Asians might be higher than that in Caucasians. This information might prove to be helpful in screening candidates for relevant treatments.

MATERIALS AND METHODS {#s4}
=====================

Search strategy {#s4_1}
---------------

We conducted a systematic search of PubMed, Embase, and Cochrane databases for articles published from inception to July 2015. The following keywords were used: "PD-L1" or "B7-H1" or "CD274" or "PD-1" or "CD279" or "programmed cell death 1" combined with "cancer" or "tumor" or "carcinoma" with limits "human". An additional search through Google Scholar and a manual search through reference lists of relevant reviews were additionally performed. Three authors (ZY, KS and SJ) independently carried out the search. As Chinese investigators, we restricted our searches to studies published in either English or Chinese.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

Eligible studies fulfilled the following inclusion criteria: (i) original articles; (ii) the expression level of PD-L1 is tested by immunohistochemistry (IHC) staining on tumor cell specimens; (iii) data of the binary clinicopathological factors stratified by PD-L1 status were available. Studies that failed to meet the inclusion criteria were excluded.

Data extraction {#s4_3}
---------------

The data collection and assessment of methodological quality followed the QUORUM and the Cochrane Collaboration guidelines ([http://www.cochrane.de](http://www.cochrane.de/)). The data on lead author, publication year, tumor type, patients\' characteristics, patient origin, primary antibody, and PD-L1 status, clinicopathological features stratified by PD-L1 status were extracted by two investigators (LZY and XYT) independently. For uniformed data analysis, T1 was considered as small size, and T2, T3, and T4 as large size for CRC, EC and UC. For the histological grade, grades I and II (well/moderate differentiation) were grouped together *vs* grade III (poor differentiation). We defined large tumors in other tumor types and elder patients according to the criteria of each individual study. Reviewers (LZY and XYT) used the Newcastle-Ottawa scale specific to cohort study to assess all included studies. Discrepancies were discussed by all investigators to reach consensus. All eligible studies were of high quality.

Statistical analysis {#s4_4}
--------------------

Analysis was performed using Stata 12.0 (Stata Corporation, Texas, US) and Review Manager 5.2 (Cochrane Collaboration, Oxford, UK). The relationship between PD-L1 expression rate and antibody types, patients\' origin, and IHC evaluation methods were investigated using independent statistical t-test respectively. Comparisons of dichotomous measures were performed by pooled estimates of odds ratios (ORs), as well as their 95% CI. Subgroup analysis was conducted according to patients\' origin, primary antibody (monoclonal antibody & polyclonal antibody) and IHC evaluation method (even in different cut-off values for PD-L1 positive) respectively. All CIs had two-sided probability coverage of 95%. A statistical test with P-value less than 0.05 was considered significant.

Publication bias {#s4_5}
----------------

An extensive search strategy was made to minimize the potential publication bias. Graphical funnel plots were generated to visually assess publication bias. The statistical method to detect funnel plot asymmetry was the Begg\'s test.

SUPPLEMENTARY FIGURE {#s5}
====================
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